COVID-19 triggers growing interest of European patients in where drugs are manufactured: Teva study
![](/46/pdcnewsitem/11/45/76/HLN00CPO_Europe_Pill_784x590.jpg)
Just as 'food miles' have become a key concern among consumers in recent years, patients now want to know more about 'medicine miles', study commissioned by Teva finds
The coronavirus pandemic has triggered growing interest among European patients about where their drugs are manufactured and Europe's wider role in drug production, according to a report commissioned by generics comapny, Teva.
The study, which questioned 3,000 European patients who rely on regular medication for chronic conditions revealed seven out of 10 are now keen to know where their medicines are made while 71% of respodents said they are interested in knowing Europe remains as competitive as other regions.
The vast majority (84%) of patients surveyed said they wanted their government to support pharmaceutical manufacturing investments in their region to avoid over-dependencies on countries outside of Europe.
This patient interest comes as the pandemic has exposed "weaknesses in the growing concentration of essential medicine production overseas and highlights the need to rebalance the global pharmaceutical value chain to ensure every region around the world has reliable access to vital medicines," Teva said.
The COVID-19 pandemic has highlighted problems with global supply chains caused by a large proportion of global API production being clustered in Asia.
Although Europe remains strong in producing finished medicines it has lost its leadership position in API manufacturing in the off-patent generics sector — particularly for drugs such as paracetamol— opening up strategic vulnerabilities.
Richard Daniell, Executive Vice President for Teva in Europe, said the pandemic has acted as a "wake-up call" and that the growing imbalance of the global pharmaceutical value chain cannot continue.
The report suggests Europe’s over-reliance on overseas API manufacturing has been "exposed by the closure of factories and borders, and that nationalistic approaches don’t work in such a highly connected and interdependent area as modern medicine supply."
Teva said that Europe must, therefore, adjust its policies to new economic and technological realities, while expanding its competitiveness and geopolitical position by remaining open and attracting investments.
Daniell also said that Europe’s regulatory regime, which he describes as "rather inflexible" and "old fashioned" should be modernised to attract pharmaceutical investments to produce critical APIs and generic medicines.
Furthermore, he added that seizing this "watershed moment" to create a new equilibrium will not simply improve Europe's resilience, it will also deliver a significant economic contribution to the region and be more sustainable given the potential of transport reduction-related environmental impact.
![TEVA](https://www.cphi-online.com/c256510th_S-comp256510.jpg)
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News GSK spins off consumer arm Haleon in biggest European listing for a decade
Haleon becomes the world’s biggest consumer health business, but debuted with a lower-than-expected valuation -
News SIGA reports $28M worth of new orders for monkeypox antiviral
The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally -
News New CPHI report looks at CDMO outsourcing and partner selection
In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies ... -
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance